SPONSOR
MediLink Therapeutics (Suzhou) Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 3
MediLink Therapeutics (Suzhou) Co., Ltd. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Metastatic Castration-resistant Prostate Cancer (mCRPC), Nasopharyngeal Carcinoma.
The trial portfolio spans Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — MediLink Therapeutics (Suzhou) Co., Ltd.
How many clinical trials has MediLink Therapeutics (Suzhou) Co., Ltd. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by MediLink Therapeutics (Suzhou) Co., Ltd., of which 2 are actively recruiting participants. These trials cover conditions including Metastatic Castration-resistant Prostate Cancer (mCRPC), Nasopharyngeal Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does MediLink Therapeutics (Suzhou) Co., Ltd. research focus on?
MediLink Therapeutics (Suzhou) Co., Ltd. clinical trials span Metastatic Castration-resistant Prostate Cancer (mCRPC), Nasopharyngeal Carcinoma. The research pipeline includes Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a MediLink Therapeutics (Suzhou) Co., Ltd. clinical trial?
To participate in a MediLink Therapeutics (Suzhou) Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all MediLink Therapeutics (Suzhou) Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by MediLink Therapeutics (Suzhou) Co., Ltd.
NCT06241846 Phase 2
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06629597 Phase 3
Recruiting
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology